Relationship between disease awareness and severity of kidney disease in autosomal dominant polycystic kidney disease patients

Polycystic kidney disease (PKD) is responsible for 5%–10% of end‐stage renal disease. We examined the relationship between renal and extrarenal findings, disease severity, and the level of consciousness of PKD patients.

[1]  K. Ateş,et al.  Current Status of Renal Replacement Therapy in Turkey: A Summary of the Turkish Society of Nephrology Registry Report , 2020, Turkish Journal of Nephrology.

[2]  I. Kocyiğit,et al.  Multiple urinary tract infections are associated with genotype and phenotype in adult polycystic kidney disease , 2019, Clinical and Experimental Nephrology.

[3]  L. Clark,et al.  Cost-effectiveness of angiotensin-converting enzyme inhibitors versus angiotensin II receptor blockers as first-line treatment in autosomal dominant polycystic kidney disease , 2017, Journal of medical economics.

[4]  P. McFarlane,et al.  Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease , 2017, Canadian journal of kidney health and disease.

[5]  H. Rennert,et al.  Autosomal dominant polycystic kidney disease caused by somatic and germline mosaicism , 2015, Clinical genetics.

[6]  Ajay V. Srivastava,et al.  Autosomal dominant polycystic kidney disease. , 2014, American family physician.

[7]  L. Pączek,et al.  Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease , 2013, American Journal of Neuroradiology.

[8]  P. Gabow,et al.  Hypertension in autosomal dominant polycystic kidney disease , 2013 .

[9]  Douglas Landsittel,et al.  Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease. , 2012, Clinical journal of the American Society of Nephrology : CJASN.

[10]  C. Patch,et al.  Use of antihypertensive medications and mortality of patients with autosomal dominant polycystic kidney disease: a population-based study. , 2011, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[11]  V. Torres,et al.  A case for water in the treatment of polycystic kidney disease. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[12]  C. Schmid,et al.  A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.

[13]  J. Grantham,et al.  Clinical practice. Autosomal dominant polycystic kidney disease. , 2008, The New England journal of medicine.

[14]  J. Feingold,et al.  Estimating prevalence in single-gene kidney diseases progressing to renal failure. , 2000, Kidney international.

[15]  E. Coto,et al.  Comparison of phenotypes of polycystic kidney disease types 1 and 2 , 1999, The Lancet.

[16]  P. Gabow,et al.  Hereditary and acquired cystic disease of the kidney. , 1994, Kidney international.

[17]  Brenda R. Hemmelgarn,et al.  Notice , 2012, Kidney International Supplements.

[18]  B. Kasiske,et al.  KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease Foreword , 2013 .

[19]  A. Paterson,et al.  Unified criteria for ultrasonographic diagnosis of ADPKD. , 2009, Journal of the American Society of Nephrology : JASN.

[20]  K. Petrie,et al.  The illness perception questionnaire: A new method for assessing the cognitive representation of illness , 1996 .